Experienced in Virus Associated Hemophagocytic Syndrome

Dr. Casey L. O'connell

Hematology Oncology | Hematology | Oncology
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
Offers Telehealth
Experienced in Virus Associated Hemophagocytic Syndrome
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell is rated as an Experienced provider by MediFind in the treatment of Virus Associated Hemophagocytic Syndrome. Her top areas of expertise are Polycythemia Vera, Myelofibrosis, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Keck Hospital Of USC
USC Verdugo Hills Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Optima Health
  • HMO
  • POS
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

USC CARE MEDICAL GROUP INC
1520 San Pablo St, Los Angeles, CA 90033
Other Locations
USC CARE MEDICAL GROUP INC
1441 Eastlake Ave, Suite 2424, Los Angeles, CA 90089
USC CARE MEDICAL GROUP INC
1500 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Guadecitabine
Study Phase: Phase 1/Phase 2
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drug: TAS1553
Study Phase: Phase 1
Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1
Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Not Applicable
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent
A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: April 18, 2019
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

59 Total Publications

Novel approaches to the use of hypomethylating agents in myeloid malignancies.
Novel approaches to the use of hypomethylating agents in myeloid malignancies.
Journal: Epigenomics
Published: September 25, 2025
Similar Doctors
Advanced in Virus Associated Hemophagocytic Syndrome
Dr. Phillis Wu
Hematology Oncology | Hematology | Oncology
Advanced in Virus Associated Hemophagocytic Syndrome
Dr. Phillis Wu
Hematology Oncology | Hematology | Oncology
14445 Olive View Dr Rm 6b119-h, 
Sylmar, CA 
 (22.9 miles away)
818-364-3031
Languages Spoken:
English
See accepted insurances

Phillis Wu is a Hematologist Oncology specialist and a Hematologist in Sylmar, California. Dr. Wu is rated as an Advanced provider by MediFind in the treatment of Virus Associated Hemophagocytic Syndrome. Her top areas of expertise are Virus Associated Hemophagocytic Syndrome, Inflammatory Breast Cancer, Stomach Cancer, and Essential Thrombocythemia.

Advanced in Virus Associated Hemophagocytic Syndrome
Dr. Raghuveer Ranganathan
Hematology Oncology | Hematology | Oncology
Advanced in Virus Associated Hemophagocytic Syndrome
Dr. Raghuveer Ranganathan
Hematology Oncology | Hematology | Oncology
1441 Eastlake Ave, 
Los Angeles, CA 
 (0.2 miles away)
323-865-3950
Languages Spoken:
English
See accepted insurances

Raghuveer Ranganathan is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Ranganathan is rated as an Advanced provider by MediFind in the treatment of Virus Associated Hemophagocytic Syndrome. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Virus Associated Hemophagocytic Syndrome
Dr. Hung N. Tran
Hematology | Oncology | Hematology Oncology
Experienced in Virus Associated Hemophagocytic Syndrome
Dr. Hung N. Tran
Hematology | Oncology | Hematology Oncology

Los Angeles Medical Center

4950 W Sunset Blvd, 
Los Angeles, CA 
 (5.9 miles away)
833-574-2273
Languages Spoken:
English

Hung Tran is a Hematologist Oncology specialist and an Oncologist in Los Angeles, California. Dr. Tran is rated as an Advanced provider by MediFind in the treatment of Virus Associated Hemophagocytic Syndrome. His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Acute Lymphoblastic Leukemia (ALL), and Langerhans Cell Histiocytosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'connell's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 40 Advanced Conditions
View All 105 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile